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Novel Point Mutations of the ATP2A2 Gene in Two Chinese
Families with Darier Disease
To the Editor
Darier disease (DD; keratosis follicularis; MIM# 124200) is an
autosomal dominant skin disorder characterized by warty
papules with distribution over seborrheic areas (Burge and
Wilkinson, 1992). The disease usually presents in the ®rst or
second decade of life. Heat, humidity, and UV often exacerbate
the symptoms. Recently, the cause of DD was identi®ed to be
due to mutations in the ATP2A2 gene on chromosome 12q23±
24.1 (Sakuntabhai et al, 1999). A spectrum of missense,
nonsense, frameshift, and splicing mutation has since been
described in many families with DD (Jacobsen et al, 1999;
Ruiz-Perez et al, 1999). The ATP2A2 gene encodes sarco-
endoplasmic reticulum Ca2+ ATPase type 2 (SERCA2), a Ca2+
pump that plays an important role in intracellular Ca2+
signaling. SERCA2 maintains a low cytosolic Ca2+ concentra-
tion by transporting Ca2+ from the cytosol into the lumen of
the sarco/endoplasmic reticulum. Evidence for the role of
SERCA2 in the formation of the intercellular junction has also
been recognized (Stuart et al, 1996). Alternative splicing of the
ATP2A2 gene produces two isoforms, SERCA2a and
SERCA2b, which differ in their carboxy-terminal domains
and have distinct tissue expression patterns (Lytton and
MacLennan, 1988). Here we report two novel point mutations
in the ATP2A2 gene in two Chinese families with DD.
The proband in Family A (proband A; Fig 1) was a 30-y-old
male who presented with pruritic, brown, keratotic papules on his
face and trunk, reported to have commenced at the age of 15 y. He
also had raised keratoses on his palms and soles, beginning at the age
of 17 y. The proband in Family B (proband B; Fig 1) was a 40-y-
old female who exhibited pruritic warty papules on her trunk. She
reported their onset to have occured at age 7 y. Both individuals
stated that their skin lesions worsened in summer. All affected
members of the two families showed clinic manifestations similar to
that of the probands. Blood samples and skin biopsies were
obtained after the patients gave informed consent. Genomic DNA
was extracted from peripheral blood lymphocytes and each of the
21 exons of the ATP2A2 gene were ampli®ed by polymerase chain
reaction (PCR) (primer sequences and conditions previously
described; Ruiz-Perez et al, 1999). PCR-ampli®ed DNA fragments
were analyzed using SSCP (single strand conformational poly-
morphism analysis) to look for abnormal gel migration. Fragments
showing altered migration patterns were PCR-puri®ed (Qiagen,
Hilden, Germany) and sequenced bi-directionally using an ABI
Model 377 automated sequencer.
Light microscopic examination of the biopsy material showed focal
suprabasal acantholysis and dyskeratotic cells. Electron-microscopic
examination suggested aggregated tono®laments around nuclei and
decreased desmosomes on the lateral borders of basal cells.
On SSCP, each of the two probands demonstrated extra bands in
a single exon. In Family A, the extra band in exon 5 was sequenced
and revealed a heterozygous point mutation of G to A at position
445 in exon 5 of the APT2A2 gene. This mutation is expected to
cause replacement of the normal aspartic acid by asparagine
(D149N) in the resultant protein (Fig 2). The proband from family
B was found to have abnormal migration of fragments derived from
exon 19. Sequencing of the extra exon 19 band identi®ed by SSCP
showed a heterozygous point mutation of C to A at position 2747
in exon19, which changes codon 916 from serine to tyrosine
(S916Y) in the resultant protein (Fig 2). These abnormalities were
not found in any of the unaffected family members or in 50
unrelated healthy individuals.
At least 80 different pathogenic mutations have been identi®ed in
the ATP2A2 gene in DD. These include nucleotide substitutions
causing missense or nonsense mutations (N = 42), nucleotide
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Figure 1. Pedigrees of the two DD families. Solid symbols, affected
individuals; open symbols, unaffected; squares, male; circles, female;
arrows, probands.
Figure 2. Sequence analysis of the ATP2A2 gene. (A) Sequencing data
of proband A. Arrowhead denotes a nucleotide transition of C to A
(G445A) in one allele of exon 5 of ATP2A2 gene. Sequencing of the
complementary strand con®rms the change. (B) Sequencing data of
proband B. Arrowhead shows a nucleotide transversion of C to A
(C2747A) in one allele of exon 19 of ATP2A2 gene. Sequencing of the
opposite strand con®rms this transversion.
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substitutions resulting in splice mutations (N = 10), small deletions
(N = 20), small insertions (N = 6), gross deletion or gross insertion
(N = 2). The missense mutations we describe here, D149N and
S916Y, have not been described previously. They affect regions of the
protein that encode b strand and transmembrane domains, which
have been shown to be highly conserved during evolution, as all
known SERCA2 proteins from different species exhibit 100%
identity in these domains. The D149N and S916Y mutations may
alter the function of these important SERCA2 domains and, as a
consequence, impair cell adhesion and differentiation of epidermis.
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Epidermolysis Bullosa Carrier Frequencies in the US
Population
To the Editor:
Epidermolysis bullosa (EB) is a group of heritable blistering
disorders in which three major subtypes have been recognized on
the basis of clinical, genetic, and ultrastructural features: the simplex
(EBS: OMIM 601001, 131800, 131900, 131950, 131760),
junctional (JEB: OMIM 226700, 226650, 226730), and dystrophic
(DEB: OMIM 226600, 131705, 131850, 131750, 132000) forms
(Fine et al, 2000). Our laboratory has been involved in the
elucidation of the genes and mutations causing two of the major
subtypes, JEB and DEB, and has been performing genetic analysis
of patients and their families over the last several years (Pulkkinen
and Uitto, 1999). During the course of these studies we are
frequently consulted about families with an affected child as to the
recurrence risk and the type of genetic testing available. Frequently,
siblings and other family members become involved and are
concerned about their carrier status and their risk of having affected
children. Through these inquiries, it has come to our attention that
there is no published estimate of the population carrier risk of each
of the three forms of EB. Recent information compiled by the
National EB Registry (NEBR) (Fine et al, 1999) estimates the
incidence of each form of EB in the US population. From these
data population carrier frequencies can be calculated assuming
Hardy±Weinberg equilibrium. The data in Table I indicate the
results of these calculations using the incidence data presented by
Fine et al (1999). Since both dominant and recessive forms of EBS
and DEB are recognized, some caution must be exercised in
interpreting the data. Until mutation analysis has proven otherwise,
inheritance pattern is generally inferred from the pedigree. EBS,
usually autosomal dominant, may manifest with relatively mild
phenotype, which is elucidated only upon close examination and
questioning of the patient and his/her family. Alternately, EBS may
manifest with a much more severe phenotype, which is usually
identi®ed in the neonatal period. In addition, a few cases of
recessively inherited EBS have been described (Chan et al, 1994;
Rugg et al, 1994; Jonkman et al, 1996), which may be more severe
than most dominant cases, although the EBS phenotype may not be
a good predictor of inheritance pattern. Based on this information,
the majority of EBS cases may be considered to have a dominant
inheritance pattern. Similarly, dominant DEB is generally milder
than the recessive forms of dystrophic EB, particularly the
Hallopeau-Siemens type; however, a number of cases in which
mutations have been identi®ed by this laboratory (Christiano et al,
1996; JaÈrvikallio et al, 1997) and others (Gardella et al, 1996; Tamai
et al, 1999) indicate that milder forms of recessive dystrophic EB are
not uncommon, and these cases, in the absence of family history,
are clinically indistinguishable from mild, de novo dominantly
inherited DEB. On the other hand, dominant DEB cases are more
Table I. Carrier frequency of major EB subtypes in the US population
EB type Incidence per 106 Prevalence per 106 Carrier frequencya Carrier frequency as fraction
EB simplex 10.75 4.6 10.75 3 10±6
Junctional EB
All 2.04 0.44 2.86 3 10±3 1/333
Herlitz 0.41 0.07 1.28 3 10±3 1/781
Dystrophic EB
Dominant 2.86 0.99 2.86 3 10±6
Recessive 2.04 0.92 2.86 3 10±3 1/345
Unknown 0.82 0.47 1.81 3 10±3 1/556
aFor dominant disorders the carrier frequency is quoted as incidence in US population.
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